Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Annual Information Update

26th Jun 2008 10:56

RNS Number : 5530X
Vernalis PLC
26 June 2008
 



VERNALIS PLC

ANNUAL INFORMATION UPDATE

As required under Prospectus Rule 5.2, and following publication of the Annual Report on 27th May 2008the following summarises the information and documents published or made available to the public by the Company between 24th May 2007 and 26th June 2008 inclusive.

This Annual Information Update is also being made available on the Investors section of the Company's website at www.vernalis.com.

The information referred to in this Annual Information Update was correct at the time it was published but some information may now be out of date.

1. Announcements made via a Regulatory Information Service ("RIS")

 

Date 

Description of Contents of Announcement

23/05/2007

AGM Statement 

04/06/2007

Director's Share Dealing

06/06/2007

Director/PDMR Shareholding 

11/06/2007

Phase III Data demonstrates short term prevention treatment with Frova® reduces frequency and severity of menstrual migraine

16/07/2007

Positive outcome of Phase IIa Trial of V3381 in diabetic neuropathic pain

02/08/2007

Holdings(s) in Company 

07/08/2007

Annual Information Update

17/08/2007

Update on Frova® - FDA requested extension of review date

28/08/2007

Departure of Board Member

03/09/2007

Milestone payment in Hsp90 inhibitor collaboration with Novartis

10/09/2007

FDA advises new target action date on Frova® sNDA is 30 September 2007

10/09/2007

Notice of Results

13/09/2007

Interim Results - Part 1

13/09/2007

Interim Results - Part 2

13/09/2007

Interim Results - Part 3

13/09/2007

Striking weight loss in Phase I Study V24343 in overweight and mildly obese volunteers

01/10/2007

Action Letter from FDA on Frova® sNDA

03/10/2007

Director/PDMR Shareholding

04/10/2007

Director/PDMR Shareholding

25/10/2007

Director/PDMR Shareholding

12/11/2007

Director/PDMR Shareholding

12/11/2007

Present at PJ Conference

16/11/2007

Director/PDMR Shareholding

21/12/2007

Payment of Deferred Consideration due under agreement for acquisition of Cita NeuroPharmaceuticals Inc and application for listing

03/01/2008

Holding(s) in Company

04/01/2008

Holding(s) in Company

04/01/2008

Holding(s) in Company

16/01/2008

Holding(s) in Company

17/01/2008

Holding(s) in Company

21/01/2008

Holding(s) in Company

29/01/2008

Holding(s) in Company

30/01/2008

Holding(s) in Company

15/02/2008

Holding(s) in Company

20/02/2008

Management Changes

20/02/2008

Settlement of $56m Endo Loan and Major Business Restructuring

08/04/2008

Update on Frova® sNDA

21/04/2008

Paul Capital Healthcare €18.4m Financing Agreement

21/04/2008

Notice of Results

25/04/2008

Preliminary Results - Part 1

25/04/2008

Preliminary Results - Part 2

05/06/2008

Interim Management Statement for the Period 1 January 2008 to 5 June 2008

05/06/2008

Sale of Apokyn® and US Commercial Operations, Share Subscription and EGM

06/06/2008

2007 Annual Report and Accounts and AGM Notification

06/06/2008

Publication of Combined Circular and Prospectus

26/06/2008

AGM Statement

All of the above UK regulatory announcements have been made via a RIS and can be obtained from the London Stock Exchange's website at www.londonstockexchange.com or the Company's website at www.vernalis.com. 

2. Documents filed at Companies House

All the documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated.

Date

Document Type

25/05/2007

Annual Report and Accounts

30/05/2007

Annual General Meeting Resolutions

21/08/2007

Form 363s - Annual Return

28/09/2007

Form 288b - Resignation of Director

29/10/2007

Form 288c - Change of Particulars for Director

01/02/2008

Form 88(2) - Return of Allotment of Shares

07/03/2008

Form 288b - Resignation of Director

Copies of the above documents, filed with the Registrar of Companies, can be obtained from the Companies House website at www.companieshouse.gov.uk, or can be obtained from Companies House, Crown WayCardiffCF14 3UZ.

 

3. Documents published or sent to Shareholders or filed with the UK Listing Authority or submitted to the FSA

All the documents below were submitted to the FSA/UKLA on or around the dates indicated.

Date

Document

13/09/2007

Interim Report

20/12/2007

Application for Admission of Securities to the Official List

20/12/2007

Form 1 - Application for Admission of Securities to Trading

25/04/2008

Preliminary Report

27/05/2008

Annual ReportNotice of AGM and Consent Letter

05/06/2008

Prospectus and Notice of EGM

Certain documents submitted to the FSA can be viewed at the Document Viewing Facility situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.

The Notice of Annual General Meeting and Annual, Interim and Preliminary Reports are also available via the Investors section of the Company's website at www.vernalis.com.

4. Documents lodged with the Securities and Exchange Commission

The documents listed below were filed with the SEC on or around the dates indicated.

Date

Document

04/06/2007

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

04/06/2007

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

04/06/2007

Form 15F-12G - Securities registration termination of foreign private issuers [Section 12(g)]

04/06/2007

Form F-6 POS - Post-effective amendments for immediately effective filing

Copies of the above documents are available for viewing on the Securities and Exchange Commission website at www.sec.gov.

5. Further Information

Further information about Vernalis plc can be found on the Company's website at www.vernalis.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AIUGGGZVVKVGRZM

Related Shares:

Vernalis PLC
FTSE 100 Latest
Value8,877.82
Change27.19